BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McKoy JM, Stonecash RE, Cournoyer D, Rossert J, Nissenson AR, Raisch DW, Casadevall N, Bennett CL. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008;48:1754-62. [PMID: 18482185 DOI: 10.1111/j.1537-2995.2008.01749.x] [Cited by in Crossref: 120] [Cited by in F6Publishing: 102] [Article Influence: 8.6] [Reference Citation Analysis]
Number Citing Articles
1 Rup B, Pallardy M, Sikkema D, Albert T, Allez M, Broet P, Carini C, Creeke P, Davidson J, De Vries N, Finco D, Fogdell-Hahn A, Havrdova E, Hincelin-Mery A, C Holland M, H Jensen PE, Jury EC, Kirby H, Kramer D, Lacroix-Desmazes S, Legrand J, Maggi E, Maillère B, Mariette X, Mauri C, Mikol V, Mulleman D, Oldenburg J, Paintaud G, R Pedersen C, Ruperto N, Seitz R, Spindeldreher S, Deisenhammer F; ABIRISK Consortium. Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. Clin Exp Immunol 2015;181:385-400. [PMID: 25959571 DOI: 10.1111/cei.12652] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 7.9] [Reference Citation Analysis]
2 Frahm GE, Cameron BE, Smith JC, Johnston MJ. Generation of fatty acids from 1,2-dipalmitoyl-sn-glycero-3-phosphocholine/cardiolipin liposomes that stabilize recombinant human serum albumin. J Liposome Res 2013;23:101-9. [PMID: 23294393 DOI: 10.3109/08982104.2012.747535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Mesgarpour B, Heidinger BH, Roth D, Schmitz S, Walsh CD, Herkner H. Harms of off-label erythropoiesis-stimulating agents for critically ill people. Cochrane Database Syst Rev 2017;8:CD010969. [PMID: 28841235 DOI: 10.1002/14651858.CD010969.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
4 Ichinose Y, Seto T, Nishiwaki Y, Ohe Y, Yamada Y, Takeda K, Saijo N, Hotta T. Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy. Jpn J Clin Oncol 2010;40:521-9. [PMID: 20508073 DOI: 10.1093/jjco/hyq017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
5 Edwards BJ, Bunta AD, Lane J, Odvina C, Rao DS, Raisch DW, McKoy JM, Omar I, Belknap SM, Garg V, Hahr AJ, Samaras AT, Fisher MJ, West DP, Langman CB, Stern PH. Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. J Bone Joint Surg Am 2013;95:297-307. [PMID: 23426763 DOI: 10.2106/JBJS.K.01181] [Cited by in Crossref: 73] [Cited by in F6Publishing: 25] [Article Influence: 8.1] [Reference Citation Analysis]
6 Moore E, Bellomo R. Erythropoietin (EPO) in acute kidney injury. Ann Intensive Care 2011;1:3. [PMID: 21906325 DOI: 10.1186/2110-5820-1-3] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 6.0] [Reference Citation Analysis]
7 Guinn D, Madabushi R, Wang YM, Brodsky E, Zineh I, Maxfield K. Communicating Immunogenicity-Associated Risk in Current U.S. FDA Prescription Drug Labeling: A Systematic Evaluation. Ther Innov Regul Sci 2020;54:1363-71. [PMID: 33258100 DOI: 10.1007/s43441-020-00161-z] [Reference Citation Analysis]
8 Lauria G, Campanella A, Filippini G, Martini A, Penza P, Maggi L, Antozzi C, Ciano C, Beretta P, Caldiroli D, Ghelma F, Ferrara G, Ghezzi P, Mantegazza R. Erythropoietin in amyotrophic lateral sclerosis: A pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Amyotrophic Lateral Sclerosis 2009;10:410-5. [DOI: 10.3109/17482960902995246] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
9 Dumont F, Bischoff P. Non-erythropoietic tissue-protective peptides derived from erythropoietin: WO2009094172. Expert Opinion on Therapeutic Patents 2010;20:715-23. [DOI: 10.1517/13543771003627464] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
10 Falasca K, Ucciferri C, Mancino P, Gorgoretti V, Pizzigallo E, Vecchiet J. Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response. J Med Virol 2010;82:49-56. [PMID: 19950239 DOI: 10.1002/jmv.21657] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
11 Felix T, Jordan JB, Akers C, Patel B, Drago D. Current state of biologic pharmacovigilance in the European Union: improvements are needed. Expert Opinion on Drug Safety 2019;18:231-40. [DOI: 10.1080/14740338.2019.1577818] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
12 Aoki KR. Pharmacology, immunology, and current developments. In: Benedetto AV, editor. Botulinum Toxins in Clinical Aesthetic Practice. Informa Healthcare; 2011. pp. 1-14. [DOI: 10.3109/9781841847559.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Brinks V, Weinbuch D, Baker M, Dean Y, Stas P, Kostense S, Rup B, Jiskoot W. Preclinical Models Used for Immunogenicity Prediction of Therapeutic Proteins. Pharm Res 2013;30:1719-28. [DOI: 10.1007/s11095-013-1062-z] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
14 Everds NE, Tarrant JM. Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans. Toxicol Pathol 2013;41:280-302. [PMID: 23471185 DOI: 10.1177/0192623312467400] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
15 Papadopoulou LC, Tsiftsoglou AS. Transduction of human recombinant proteins into mitochondria as a protein therapeutic approach for mitochondrial disorders. Pharm Res 2011;28:2639-56. [PMID: 21874377 DOI: 10.1007/s11095-011-0546-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
16 Hinderer W. Biosimilar Drugs. In: Kayser O, Warzecha H, editors. Pharmaceutical Biotechnology. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2012. pp. 285-335. [DOI: 10.1002/9783527632909.ch13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Sahni DR, Feldman SR. Heterogeneity and variation of innovator biologics. J Eur Acad Dermatol Venereol 2019;33:e161-3. [PMID: 30451328 DOI: 10.1111/jdv.15355] [Reference Citation Analysis]
18 Johnston MJ, Nemr K, Hefford MA. Influence of bovine serum albumin on the secondary structure of interferon alpha 2b as determined by far UV circular dichroism spectropolarimetry. Biologicals 2010;38:314-20. [DOI: 10.1016/j.biologicals.2009.11.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
19 Mueller MM, Bialleck H, Bomke B, Brauninger S, Varga C, Seidl C, Seifried E, Tonn T, Bonig H. Safety and efficacy of healthy volunteer stem cell mobilization with filgrastim G-CSF and mobilized stem cell apheresis: results of a prospective longitudinal 5-year follow-up study. Vox Sang 2013;104:46-54. [PMID: 22827736 DOI: 10.1111/j.1423-0410.2012.01632.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
20 Foley RN. Treatment of anemia in chronic kidney disease: known, unknown, and both. J Blood Med 2011;2:103-12. [PMID: 22287869 DOI: 10.2147/JBM.S13066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Tamilvanan S, Raja NL, Sa B, Basu SK. Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body. Journal of Drug Targeting 2010;18:489-98. [DOI: 10.3109/10611861003649746] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
22 Herrington W, Wieser C, Rosenkranz AR. Pure red cell aplasia after treatment of renal anaemia with epoetin theta. Clin Kidney J 2013;6:539-42. [PMID: 26120448 DOI: 10.1093/ckj/sft085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Lissy M, Ode M, Roth K. Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study. Drugs R D 2011;11:61-75. [PMID: 21410296 DOI: 10.2165/11588270-000000000-00000] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
24 Yoon S, Rhee SJ, Heo SJ, Oh TY, Yoon SH, Cho JY, Lee S, Yu KS. Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon® and Eprex® following a single subcutaneous administration in healthy male volunteers. Drug Des Devel Ther 2017;11:3127-35. [PMID: 29138535 DOI: 10.2147/DDDT.S142673] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
25 Meunier S, de Bourayne M, Hamze M, Azam A, Correia E, Menier C, Maillère B. Specificity of the T Cell Response to Protein Biopharmaceuticals. Front Immunol 2020;11:1550. [PMID: 32793213 DOI: 10.3389/fimmu.2020.01550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Shin SK, Ha SK, Lee KW, Yoo T, Yun S, Yoon S, Kim S, Lee S, Heo T. Application of a bridging ELISA for detection of anti-erythropoietin binding antibodies and a cell-based bioassay for neutralizing antibodies in human sera. Journal of Pharmaceutical and Biomedical Analysis 2010;52:289-93. [DOI: 10.1016/j.jpba.2010.01.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
27 Yin L, Chen X, Vicini P, Rup B, Hickling TP. Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products. Cellular Immunology 2015;295:118-26. [DOI: 10.1016/j.cellimm.2015.03.002] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 7.1] [Reference Citation Analysis]
28 Leung LK, Mok K, Liu C, Chan SL. What do oncologists need to know about biosimilar products? Chin J Cancer 2016;35:91. [PMID: 27733189 DOI: 10.1186/s40880-016-0151-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
29 Vandivort TC, Horton DB, Johnson SB. Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs. J Clin Transl Sci 2020;4:547-55. [PMID: 33948231 DOI: 10.1017/cts.2020.493] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Shimizu H, Saitoh T, Ota F, Jimbo T, Tsukada Y, Murakami H, Nojima Y. Pure Red Cell Aplasia Induced Only by Intravenous Administration of Recombinant Human Erythropoietin. Acta Haematol 2011;126:114-8. [DOI: 10.1159/000328041] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
31 Means RT. Anemia of Renal Failure/Chronic Kidney Disease. In: Means RT, editor. Anemia in the Young and Old. Cham: Springer International Publishing; 2019. pp. 147-56. [DOI: 10.1007/978-3-319-96487-4_8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
32 Padhi S, Panda SK. Acquired Pure Red Cell Aplasia and Recombinant Erythropoietin. Indian J Nephrol 2021;31:331-5. [PMID: 34584346 DOI: 10.4103/ijn.IJN_229_20] [Reference Citation Analysis]
33 Macdougall IC, Casadevall N, Locatelli F, Combe C, London GM, Di Paolo S, Kribben A, Fliser D, Messner H, McNeil J, Stevens P, Santoro A, De Francisco AL, Percheson P, Potamianou A, Foucher A, Fife D, Mérit V, Vercammen E; PRIMS study group. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol Dial Transplant 2015;30:451-60. [PMID: 25239637 DOI: 10.1093/ndt/gfu297] [Cited by in Crossref: 47] [Cited by in F6Publishing: 30] [Article Influence: 5.9] [Reference Citation Analysis]
34 Weise M, Bielsky M, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim H, Heinonen E, Ho K, Moreau A, Narayanan G, Kruse NA, Reichmann G, Thorpe R, van Aerts L, Vleminckx C, Wadhwa M, Schneider CK. Biosimilars: what clinicians should know. Blood 2012;120:5111-7. [DOI: 10.1182/blood-2012-04-425744] [Cited by in Crossref: 226] [Cited by in F6Publishing: 187] [Article Influence: 22.6] [Reference Citation Analysis]
35 Prus KM, Al-Rahawan MM. Recovery of native erythropoietin in a patient with erythropoietin-associated pure red cell aplasia. Pediatr Nephrol 2014;29:161-2. [PMID: 23917451 DOI: 10.1007/s00467-013-2580-y] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Civoli F, Kasinath A, Cai XY, Wadhwa M, Exley A, Oldfield P, Alvandkouhi S, Schaffar G, Chappell J, Bowsher R, Devanarayan V, Marini J, Rebarchak S, Anderson M, Koppenburg V, Lester T. Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs. AAPS J 2019;22:7. [PMID: 31792633 DOI: 10.1208/s12248-019-0386-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Sauerborn M, van Beers MMC, Jiskoot W, Kijanka GM, Boon L, Schellekens H, Brinks V. Antibody Response Against Betaferon® in Immune Tolerant Mice: Involvement of Marginal Zone B-cells and CD4+ T-cells and Apparent Lack of Immunological Memory. J Clin Immunol 2013;33:255-63. [DOI: 10.1007/s10875-012-9783-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
38 Buchanan A, Ferraro F, Rust S, Sridharan S, Franks R, Dean G, McCourt M, Jermutus L, Minter R. Improved drug-like properties of therapeutic proteins by directed evolution. Protein Eng Des Sel 2012;25:631-8. [PMID: 22942395 DOI: 10.1093/protein/gzs054] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
39 Duce L, Cooter ML, Mccartney SL, Lombard FW, Guinn NR. Outcomes in Patients Undergoing Cardiac Surgery Who Decline Transfusion and Received Erythropoietin Compared to Patients Who Did Not: A Matched Cohort Study. Anesthesia & Analgesia 2018;127:490-5. [DOI: 10.1213/ane.0000000000002418] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
40 Shin S, Moon SJ, Ha SK, Jo Y, Lee T, Lee YS, Kim Y, Kim DJ, Kim JK, Yoo T, Lee K, Choi SO, Kang EW, Lee KW, Kim S, Kim SK, Heo T. Immunogenicity of recombinant human erythropoietin in Korea: A two-year cross-sectional study. Biologicals 2012;40:254-61. [DOI: 10.1016/j.biologicals.2012.02.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
41 Miskowiak KW, Vinberg M, Harmer CJ, Ehrenreich H, Knudsen GM, Macoveanu J, Hansen AR, Paulson OB, Siebner HR, Kessing LV. Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. Trials 2010;11:97. [PMID: 20942940 DOI: 10.1186/1745-6215-11-97] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
42 Fernandes JC, Garrido P, Ribeiro S, Rocha-Pereira P, Bronze-da-Rocha E, Belo L, Costa E, Reis F, Santos-Silva A. Iron as the key modulator of hepcidin expression in erythroid antibody-mediated hypoplasia. Biomed Res Int 2014;2014:421304. [PMID: 25580431 DOI: 10.1155/2014/421304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Devlin SM, Bressler B, Bernstein CN, Fedorak RN, Bitton A, Singh H, Feagan BG. Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can J Gastroenterol 2013;27:567-71. [PMID: 24106727 DOI: 10.1155/2013/327120] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
44 Macdougall IC, Roger SD, de Francisco A, Goldsmith DJ, Schellekens H, Ebbers H, Jelkmann W, London G, Casadevall N, Hörl WH, Kemeny DM, Pollock C. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney International 2012;81:727-32. [DOI: 10.1038/ki.2011.500] [Cited by in Crossref: 74] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
45 Korotchkina LG, Ramani K, Balu-iyer SV. Folding Considerations for Therapeutic Protein Formulations. Molecular Biology of Protein Folding, Part A. Elsevier; 2008. pp. 255-70. [DOI: 10.1016/s0079-6603(08)00606-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
46 Fineman MS, Mace KF, Diamant M, Darsow T, Cirincione BB, Booker Porter TK, Kinninger LA, Trautmann ME. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab. 2012;14:546-554. [PMID: 22236356 DOI: 10.1111/j.1463-1326.2012.01561.x] [Cited by in Crossref: 100] [Cited by in F6Publishing: 93] [Article Influence: 10.0] [Reference Citation Analysis]
47 Hashimoto K, Harada M, Kamijo Y. Pure red cell aplasia induced by anti-erythropoietin antibodies, well-controlled with tacrolimus. Int J Hematol 2016;104:502-5. [DOI: 10.1007/s12185-016-2047-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
48 Lamanna WC, Holzmann J, Cohen HP, Guo X, Schweigler M, Stangler T, Seidl A, Schiestl M. Maintaining consistent quality and clinical performance of biopharmaceuticals. Expert Opinion on Biological Therapy 2018;18:369-79. [DOI: 10.1080/14712598.2018.1421169] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
49 Fogdell-hahn A. Antidrug Antibodies: B Cell Immunity Against Therapy. Scand J Immunol 2015;82:184-90. [DOI: 10.1111/sji.12327] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
50 Baldo BA. Side effects of cytokines approved for therapy. Drug Saf 2014;37:921-43. [PMID: 25270293 DOI: 10.1007/s40264-014-0226-z] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 10.7] [Reference Citation Analysis]
51 Ebbers HC, Mantel-teeuwisse AK, Moors EH, Schellekens H, Leufkens HG. Todayʼs Challenges in Pharmacovigilance: What can we Learn from Epoetins? Drug Safety 2011;34:273-87. [DOI: 10.2165/11586350-000000000-00000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
52 Campeau PM, Rafei M, François M, Birman E, Forner KA, Galipeau J. Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients. Mol Ther 2009;17:369-72. [PMID: 19088705 DOI: 10.1038/mt.2008.270] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
53 Halim LA, Márquez M, Maas-Bakker RF, Castañeda-Hernández G, Jiskoot W, Schellekens H. Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product. Pharm Res 2018;35:226. [PMID: 30280277 DOI: 10.1007/s11095-018-2491-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Mattison P, Upadhyay K, Wilcox JE, Moudgil A, Silverstein DM. Anti-erythropoietin antibodies followed by endogenous erythropoietin production in a dialysis patient. Pediatr Nephrol 2010;25:971-6. [PMID: 20091055 DOI: 10.1007/s00467-009-1406-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
55 Krafft A, Breymann C. Iron sucrose with and without recombinant erythropoietin for the treatment of severe postpartum anemia: A prospective, randomized, open-label study: Treatment of severe postpartum anemia. Journal of Obstetrics and Gynaecology Research 2011;37:119-24. [DOI: 10.1111/j.1447-0756.2010.01328.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
56 Bickel F, Herold EM, Signes A, Romeijn S, Jiskoot W, Kiefer H. Reversible NaCl-induced aggregation of a monoclonal antibody at low pH: Characterization of aggregates and factors affecting aggregation. European Journal of Pharmaceutics and Biopharmaceutics 2016;107:310-20. [DOI: 10.1016/j.ejpb.2016.07.020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
57 Jelkmann W. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences. Am J Hematol 2010;85:771-80. [PMID: 20706990 DOI: 10.1002/ajh.21805] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 5.8] [Reference Citation Analysis]
58 Ding J, Li QY, Yu JZ, Wang X, Lu CZ, Ma CG, Xiao BG. Carbamylated erythropoietin ameliorates hypoxia-induced cognitive and behavioral defects with the generation of choline acetyltransferase-positive neurons. J Neurosci Res 2013;91:73-82. [PMID: 23074165 DOI: 10.1002/jnr.23124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
59 Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. J Pharm Sci 2010;99:2557-75. [PMID: 20049941 DOI: 10.1002/jps.22054] [Cited by in Crossref: 366] [Cited by in F6Publishing: 345] [Article Influence: 30.5] [Reference Citation Analysis]
60 Tan CW, Tan-Koi WC, Ng J, Chan CM, Hwang WY. A cluster of Epoetin-associated pure red cell aplasia: clinical features and the possible association of HLA-DRB1*12:02. Pharmacogenomics 2016;17:1235-43. [PMID: 27348021 DOI: 10.2217/pgs-2016-0018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
61 Nelson DR, Jensen DM, Sulkowski MS, Everson G, Fried MW, Gordon SC, Jacobson I, Reau NS, Sherman K, Terrault N, Thomas D. Hepatitis C virus: a critical appraisal of new approaches to therapy. Hepat Res Treat 2012;2012:138302. [PMID: 23094146 DOI: 10.1155/2012/138302] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
62 Aapro M, Gascón P, Patel K, Rodgers GM, Fung S, Arantes LH Jr, Wish J. Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective. Front Pharmacol 2018;9:1498. [PMID: 30687083 DOI: 10.3389/fphar.2018.01498] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
63 Shingu Y, Nakata T, Sawai S, Tanaka H, Asai O, Tamagaki K, Nakatani K. Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient. BMC Nephrol 2020;21:275. [PMID: 32664894 DOI: 10.1186/s12882-020-01934-2] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 Brinks V, Hawe A, Basmeleh AH, Joachin-Rodriguez L, Haselberg R, Somsen GW, Jiskoot W, Schellekens H. Quality of original and biosimilar epoetin products. Pharm Res 2011;28:386-93. [PMID: 20886265 DOI: 10.1007/s11095-010-0288-2] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 5.8] [Reference Citation Analysis]
65 Heinemann L, Khatami H, McKinnon R, Home P. An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins. Diabetes Technol Ther 2015;17:510-26. [PMID: 25789689 DOI: 10.1089/dia.2014.0362] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
66 Schellekens H, Aldosari M, Talsma H, Mastrobattista E. Making individualized drugs a reality. Nat Biotechnol 2017;35:507-13. [PMID: 28581491 DOI: 10.1038/nbt.3888] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
67 Lippi G, Franchini M. Intermittent hypoxic training: doping or what? Eur J Appl Physiol 2010;108:411-2. [PMID: 19756707 DOI: 10.1007/s00421-009-1188-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
68 Lacaná E, Yao LP, Pariser AR, Rosenberg AS. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease. Am J Med Genet C Semin Med Genet 2012;160C:30-9. [PMID: 22253234 DOI: 10.1002/ajmg.c.31316] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
69 Schmidt LS, Petersen JZ, Vinberg M, Hageman I, Olsen NV, Kessing LV, Jørgensen MB, Miskowiak KW. Erythropoietin as an add-on treatment for cognitive side effects of electroconvulsive therapy: a study protocol for a randomized controlled trial. Trials 2018;19:234. [PMID: 29673379 DOI: 10.1186/s13063-018-2627-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 Lacreta G, Bucharles SGE, Sevignani G, Riella MC, Nascimento MMD. Pure red cell aplasia and anti-erythropoietin antibodies in patients on hemodialysis: a report of two cases and a literature review. J Bras Nefrol 2019;41:145-51. [PMID: 30160771 DOI: 10.1590/2175-8239-jbn-2018-0054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Czerwinski M, Hopper RA, Gruss J, Fearon JA. Major morbidity and mortality rates in craniofacial surgery: an analysis of 8101 major procedures. Plast Reconstr Surg 2010;126:181-6. [PMID: 20220557 DOI: 10.1097/PRS.0b013e3181da87df] [Cited by in Crossref: 71] [Cited by in F6Publishing: 17] [Article Influence: 5.9] [Reference Citation Analysis]
72 Macpherson IR, Lindsay CR, Reed NS. Recombinant human epoetin beta in the treatment of chemotherapy-related anemia. Ther Clin Risk Manag 2009;5:261-70. [PMID: 19436615 DOI: 10.2147/tcrm.s3320] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
73 Jawa V, Terry F, Gokemeijer J, Mitra-Kaushik S, Roberts BJ, Tourdot S, De Groot AS. T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020. Front Immunol 2020;11:1301. [PMID: 32695107 DOI: 10.3389/fimmu.2020.01301] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
74 Ryu JK, Kim HS, Nam DH. Current status and perspectives of biopharmaceutical drugs. Biotechnol Bioproc E 2012;17:900-11. [DOI: 10.1007/s12257-012-0095-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
75 Ferguson J, Bird C, Wadhwa M, Burns C. Detection of neutralizing antibodies to erythropoietin by inhibition of rHuEPO-stimulated EGR1 gene expression in the UT-7/EPO cell line. J Immunol Methods 2013;387:191-8. [PMID: 23142458 DOI: 10.1016/j.jim.2012.10.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
76 Wang YM, Wang J, Hon YY, Zhou L, Fang L, Ahn HY. Evaluating and Reporting the Immunogenicity Impacts for Biological Products--a Clinical Pharmacology Perspective. AAPS J 2016;18:395-403. [PMID: 26721560 DOI: 10.1208/s12248-015-9857-y] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
77 Wright DG, Wright EC, Narva AS, Noguchi CT, Eggers PW. Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States. Clin J Am Soc Nephrol 2015;10:1822-30. [PMID: 26358266 DOI: 10.2215/CJN.01590215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 3.1] [Reference Citation Analysis]
78 Wang YC, Jawa V, Ma M. Immunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis. Bioanalysis 2014;6:79-87. [DOI: 10.4155/bio.13.302] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
79 Rathore AS, Chhabra H, Bhargava A. Approval of biosimilars: a review of unsuccessful regulatory filings. Expert Opin Biol Ther 2021;21:19-28. [PMID: 32634326 DOI: 10.1080/14712598.2020.1793954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Chuengsaman P, Narenpitak S, Sritippayawan S. Efficacy and safety of recombinant human erythropoietin (Hema-Plus®) for management of anemia in Thai patients on peritoneal dialysis. World J Nephrol 2021; 10(6): 109-121 [PMID: 34909408 DOI: 10.5527/wjn.v10.i6.109] [Reference Citation Analysis]
81 Barger TE, Wrona D, Goletz TJ, Mytych DT. A detailed examination of the antibody prevalence and characteristics of anti-ESA antibodies. Nephrology Dialysis Transplantation 2012;27:3892-9. [DOI: 10.1093/ndt/gfs392] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
82 McKoy JM, Fisher MJ, Courtney DM, Raisch DW, Edwards BJ, Scheetz MH, Belknap SM, Trifilio SM, Samaras AT, Liebling DB, Nardone B, Tulas KM, West DP. Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf 2013;36:335-47. [PMID: 23553448 DOI: 10.1007/s40264-013-0042-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
83 Schmid H, Schiffl H, Lederer SR. Pharmacotherapy of end-stage renal disease. Expert Opin Pharmacother 2010;11:597-613. [PMID: 20163271 DOI: 10.1517/14656560903544494] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
84 de Ridder L, Waterman M, Turner D, Bronsky J, Hauer AC, Dias JA, Strisciuglio C, Ruemmele FM, Levine A, Lionetti P; ESPGHAN Paediatric IBD Porto Group. Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto Group. J Pediatr Gastroenterol Nutr. 2015;61:503-508. [PMID: 26154031 DOI: 10.1097/mpg.0000000000000903] [Cited by in Crossref: 30] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
85 Watson C, Sharp JS. Conformational analysis of therapeutic proteins by hydroxyl radical protein footprinting. AAPS J 2012;14:206-17. [PMID: 22382679 DOI: 10.1208/s12248-012-9336-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
86 Petersen JZ, Schmidt LS, Vinberg M, Jørgensen MB, Hageman I, Ehrenreich H, Knudsen GM, Kessing LV, Miskowiak KW. Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial. Trials 2018;19:611. [PMID: 30400939 DOI: 10.1186/s13063-018-2995-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
87 Testa U. Erythropoietic stimulating agents. Expert Opinion on Emerging Drugs 2010;15:119-38. [DOI: 10.1517/14728210903499273] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
88 Manta B, Obal G, Ricciardi A, Pritsch O, Denicola A. Tools to evaluate the conformation of protein products. Biotechnology Journal 2011;6:731-41. [DOI: 10.1002/biot.201100107] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
89 Goncalves J, Magro F, Danese S, Lakatos PL, Ben-Horin S. Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Authors' reply. Aliment Pharmacol Ther 2018;48:575-6. [PMID: 30156326 DOI: 10.1111/apt.14860] [Reference Citation Analysis]
90 Bennett CL, Starko KM, Thomsen HS, Cowper S, Sartor O, Macdougall IC, Qureshi ZP, Bookstaver PB, Miller AD, Norris LB, Xirasagar S, Trenery A, Lopez I, Kahn A, Murday A, Luminari S, Cournoyer D, Locatelli F, Ray P, Mattison DR. Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR). J Gen Intern Med 2012;27:1697-703. [PMID: 22692632 DOI: 10.1007/s11606-012-2098-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
91 Moore EM, Bellomo R, Nichol AD. Erythropoietin as a novel brain and kidney protective agent. Anaesth Intensive Care 2011;39:356-72. [PMID: 21675055 DOI: 10.1177/0310057X1103900306] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
92 Guinn D, Madabushi R, Wang YM, Zineh I, Maxfield K. Elucidating the Impact of Immunogenicity Assessment Postapproval: A Targeted Analysis of Immunogenicity Postmarketing Requirements and Commitments. Clin Pharmacol Ther 2021;109:697-704. [PMID: 32895941 DOI: 10.1002/cpt.2038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
93 Awwad S, Angkawinitwong U. Overview of Antibody Drug Delivery. Pharmaceutics 2018;10:E83. [PMID: 29973504 DOI: 10.3390/pharmaceutics10030083] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 12.3] [Reference Citation Analysis]
94 McKoy JM, Giles FJ. Biosimilars: Are They Really Safe? Cancer Treat Res 2019;171:61-73. [PMID: 30552657 DOI: 10.1007/978-3-319-43896-2_5] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
95 Koncicki HM, Fishbane S. A Woman with ESRD with Increasing Need for Erythropoietin to Maintain Hemoglobin. Clin J Am Soc Nephrol 2017;12:1173-5. [PMID: 28522653 DOI: 10.2215/CJN.01160117] [Reference Citation Analysis]
96 Behler CM, Terrault NA, Etzell JE, Damon LE. Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report. J Med Case Rep 2009;3:7335. [PMID: 19830190 DOI: 10.4076/1752-1947-3-7335] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
97 Foley RN. Emerging erythropoiesis-stimulating agents. Nat Rev Nephrol 2010;6:218-23. [DOI: 10.1038/nrneph.2010.19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
98 Kalantar-Zadeh K. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology. Am J Nephrol 2017;45:235-47. [PMID: 28142147 DOI: 10.1159/000455387] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 6.4] [Reference Citation Analysis]
99 Lucio SD, Stevenson JG, Hoffman JM. Biosimilars: Implications for health-system pharmacists. Am J Health Syst Pharm 2013;70:2004-17. [PMID: 24173009 DOI: 10.2146/ajhp130119] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
100 O'Donnell C, Michael N, Bloch N, Erickson M, Garg S. Strategies to Minimize Blood Loss and Transfusion in Pediatric Spine Surgery. JBJS Rev 2017;5:e1. [PMID: 28471775 DOI: 10.2106/JBJS.RVW.16.00064] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
101 Chen TL, Chiang YW, Lin GL, Chang HH, Lien TS, Sheh MH, Sun DS. Different effects of granulocyte colony-stimulating factor and erythropoietin on erythropoiesis. Stem Cell Res Ther 2018;9:119. [PMID: 29720275 DOI: 10.1186/s13287-018-0877-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
102 Mikulskis A, Yeung D, Subramanyam M, Amaravadi L. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development. Journal of Immunological Methods 2011;365:38-49. [DOI: 10.1016/j.jim.2010.11.011] [Cited by in Crossref: 68] [Cited by in F6Publishing: 58] [Article Influence: 6.2] [Reference Citation Analysis]
103 Jädersten M, Hellström-lindberg E. Myelodysplastic syndromes: biology and treatment. Journal of Internal Medicine 2009;265:307-28. [DOI: 10.1111/j.1365-2796.2008.02052.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
104 Niazi SK. Biosimilars: A futuristic fast-to-market advice to developers. Expert Opin Biol Ther 2021;:1-7. [PMID: 34913776 DOI: 10.1080/14712598.2022.2020241] [Reference Citation Analysis]
105 Lakhanpal A, Brahn E. Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions. Clin Rheumatol 2016;35:2869-75. [PMID: 27714482 DOI: 10.1007/s10067-016-3430-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
106 Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, Herrine SK, Harrison SA, Poordad FF, Koury K. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology. 2010;139:1602-1611, 1611.e1. [PMID: 20723545 DOI: 10.1053/j.gastro.2010.07.059] [Cited by in Crossref: 85] [Cited by in F6Publishing: 74] [Article Influence: 7.1] [Reference Citation Analysis]
107 Madeddu C, Neri M, Sanna E, Oppi S, Macciò A. Experimental Drugs for Chemotherapy- and Cancer-Related Anemia. J Exp Pharmacol 2021;13:593-611. [PMID: 34194245 DOI: 10.2147/JEP.S262349] [Reference Citation Analysis]